Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup

DOI Web Site 被引用文献10件
  • R.F. Schlenk
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • A. Benner
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • J. Krauter
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • T. Büchner
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • C. Sauerland
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • G. Ehninger
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • M. Schaich
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • B. Mohr
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • D. Niederwieser
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • R. Krahl
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • R. Pasold
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • K. Döhner
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • A. Ganser
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • H. Döhner
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...
  • G. Heil
    From the Department of Internal Medicine III, University of Ulm, Ulm; Central Unit of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg; Department of Hematology/Oncology, University of Hannover, Hannover; Department of Internal Medicine A and Department of Medical Informatics and Bioinformatics, University of Münster, Münster; Department of Internal Medicine I, University of Dresden, Dresden; Department of Hematology/Oncology, University of Leipzig, Leipzig; and Ernst von Bergmann...

抄録

<jats:sec><jats:title>Purpose</jats:title><jats:p> To evaluate prognostic factors for relapse-free survival (RFS) and overall survival (OS) and to assess the impact of different postremission therapies in adult patients with core binding factor (CBF) acute myeloid leukemias (AML). </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Individual patient data–based meta-analysis was performed on 392 adults (median age, 42 years; range, 16 to 60 years) with CBF AML (t(8;21), n = 191; inv(16), n = 201) treated between 1993 and 2002 in prospective German AML treatment trials. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> RFS was 60% and 58% and OS was 65% and 74% in the t(8;21) and inv(16) groups after 3 years, respectively. For postremission therapy, intention-to-treat analysis revealed no difference between intensive chemotherapy and autologous transplantation in the t(8;21) group and between chemotherapy, autologous, and allogeneic transplantation in the inv(16) group. In the t(8;21) group, significant prognostic variables for longer RFS and OS were lower WBC and higher platelet counts; loss of the Y chromosome in male patients was prognostic for shorter OS. In the inv(16) group, trisomy 22 was a significant prognostic variable for longer RFS. For patients who experienced relapse, second complete remission rate was significantly lower in patients with t(8;21), resulting in a significantly inferior survival duration after relapse compared with patients with inv(16). </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> We provide novel prognostic factors for CBF AML and show that patients with t(8;21) who experience relapse have an inferior survival duration. </jats:p></jats:sec>

収録刊行物

被引用文献 (10)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ